| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.IMLET.2004.11.009 |
| P698 | PubMed publication ID | 15752556 |
| P50 | author | John Clemens | Q58987399 |
| Joaquín Sánchez | Q59141346 | ||
| P2093 | author name string | Jan Holmgren | |
| Thomas Lehner | |||
| Cecil Czerkinsky | |||
| Ann-Mari Svennerholm | |||
| Carl-Fredrik Flach | |||
| Ali M Harandi | |||
| Kristina Eriksson | |||
| Sukanya Raghavan | |||
| Jenni Adamsson | |||
| Fabienne Anjuère | |||
| Michael Lebens | |||
| Michael Stanford | |||
| Jia-Bin Sun | |||
| Sara Tengvall | |||
| Marianne Lindblad | |||
| Erik Nygren | |||
| Annie George-Chandy | |||
| P2860 | cites work | Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 |
| P433 | issue | 2 | |
| P921 | main subject | cholera | Q12090 |
| P304 | page(s) | 181-188 | |
| P577 | publication date | 2004-12-07 | |
| P1433 | published in | immunology Letters | Q15766068 |
| P1476 | title | Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA | |
| P478 | volume | 97 |
| Q46425459 | A New Way to Beat Intestinal Pathogens |
| Q51062689 | A Recombinant Probiotic, Lactobacillus casei, Expressing the Clostridium perfringens α-toxoid, as an Orally Vaccine Candidate Against Gas Gangrene and Necrotic Enteritis. |
| Q82831287 | A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori |
| Q27331013 | Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice |
| Q34431983 | An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles |
| Q39658273 | Analysis of a cholera toxin B subunit (CTB) and human mucin 1 (MUC1) conjugate protein in a MUC1-tolerant mouse model |
| Q90356536 | Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera |
| Q42799481 | Broad up-regulation of innate defense factors during acute cholera |
| Q38657465 | CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway. |
| Q50065798 | Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. |
| Q34026162 | Cholera toxin - a foe & a friend. |
| Q36551840 | Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function. |
| Q42205232 | Cholera toxin B subunit-five-stranded α-helical coiled-coil fusion protein: "five-to-five" molecular chimera displays robust physicochemical stability |
| Q47913833 | Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. |
| Q35232735 | Cholera toxin B: one subunit with many pharmaceutical applications |
| Q37191283 | Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes |
| Q34739851 | Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells |
| Q37038072 | Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches |
| Q34682128 | Comparison of retinal nerve fiber layer thickness in vivo and axonal transport after chronic intraocular pressure elevation in young versus older rats |
| Q38606892 | Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit |
| Q22065315 | Complete plastid genome sequence of Daucus carota: implications for biotechnology and phylogeny of angiosperms |
| Q38016171 | Concurrent exposure to microbial products and food antigens triggers initiation of food allergy |
| Q36480147 | Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit |
| Q33787778 | Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H pylori ureB and IL-2 |
| Q37110110 | Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge |
| Q64215275 | Direct immunization of the abomasum or rectum of goats induces local lymph node responses against Haemonchus contortus mucosal antigens |
| Q35138744 | Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration. |
| Q28728791 | Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine |
| Q51964377 | Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin. |
| Q36780146 | Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells |
| Q81622100 | Expression of cholera toxin B subunit in transgenic rice endosperm |
| Q36990434 | Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts--oral administration protects against development of insulitis in non-obese diabetic mice |
| Q35598231 | Functional pentameric formation via coexpression of the Escherichia coli heat-labile enterotoxin B subunit and its fusion protein subunit with a neutralizing epitope of ApxIIA exotoxin improves the mucosal immunogenicity and protection against chall |
| Q30804405 | Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route |
| Q40020246 | Genetic diversity of heat-labile toxin expressed by enterotoxigenic Escherichia coli strains isolated from humans |
| Q36172686 | Genetically modified enterotoxigenic Escherichia coli vaccines induce mucosal immune responses without inflammation. |
| Q33738499 | Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection |
| Q27342880 | Immunoadjuvant Properties of the Rho Activating Factor CNF1 in Prophylactic and Curative Vaccination against Leishmania infantum |
| Q37473348 | Immunogenicity and protective efficacy of rotavirus VP8* fused to cholera toxin B subunit in a mouse model |
| Q33584872 | Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery |
| Q92538598 | Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections |
| Q36593534 | Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin |
| Q45129797 | Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera |
| Q34545847 | Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice |
| Q37677269 | Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses |
| Q34565122 | Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro |
| Q37451022 | Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection |
| Q38329970 | Merozoite surface protein-1 of Plasmodium yoelii fused via an oligosaccharide moiety of cholera toxin B subunit glycoprotein expressed in yeast induced protective immunity against lethal malaria infection in mice |
| Q37736005 | Mucosal HIV vaccines: a holy grail or a dud? |
| Q35191220 | Mucosal immunization with a Staphylococcus aureus IsdA-cholera toxin A2/B chimera induces antigen-specific Th2-type responses in mice |
| Q36517179 | Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity |
| Q35003962 | N-glycosylation of cholera toxin B subunit in Nicotiana benthamiana: impacts on host stress response, production yield and vaccine potential. |
| Q47979035 | Neonatal vaccination with Mycobacterium bovis BCG: potential effects as a priming agent shown in a heterologous prime-boost immunization protocol |
| Q50561743 | Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae. |
| Q50658682 | Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity. |
| Q24234435 | Oral vaccines for preventing cholera |
| Q24235775 | Oral vaccines for preventing cholera |
| Q39255935 | Physicochemically stable cholera toxin B subunit pentamer created by peripheral molecular constraints imposed by de novo-introduced intersubunit disulfide crosslinks. |
| Q37776723 | Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we? |
| Q34119427 | Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization |
| Q38108303 | Potential of immunoglobulin A to prevent allergic asthma |
| Q42744528 | Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity |
| Q54450502 | Regulation of intestinal immunity: effects of the oral adjuvant Escherichia coli heat-labile enterotoxin on migrating dendritic cells. |
| Q35140438 | Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge |
| Q50030181 | Strain dependent protection conferred by Lactobacillus spp. administered orally with a Salmonella Typhimurium vaccine in a murine challenge model. |
| Q37617455 | Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates |
| Q39684787 | Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. |
| Q34629092 | Suppression of dendritic cell activation by diabetes autoantigens linked to the cholera toxin B subunit. |
| Q34206463 | Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers |
| Q83299513 | TSLP: from allergy to vaccine adjuvant |
| Q41392262 | The Cholera Toxin B Subunit (CTB) Fused to the Porcine Arterivirus Matrix M and GP5 Envelope Proteins Fails to Enhance the GP5-Specific Antibody Response in Pigs Immunized with Adenovectors |
| Q36086244 | The FomA porin from Fusobacterium nucleatum is a Toll-like receptor 2 agonist with immune adjuvant activity |
| Q38185911 | The future for vaccine development against Entamoeba histolytica |
| Q43198955 | The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant |
| Q37192920 | The protective effect of recombinant FomA-expressing Lactobacillus acidophilus against periodontal infection |
| Q37791415 | Topical immunization strategies |
| Q42725013 | Use of stabilized luciferase-expressing plasmids to examine in vivo-induced promoters in the Vibrio cholerae vaccine strain CVD 103-HgR. |
| Q24201328 | Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea |
| Q24236078 | Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea |
Search more.